Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fabio Da Roit"'
Autor:
Fabio Da Roit, Patrick J. Engelberts, Ronald P. Taylor, Esther C.W. Breij, Giuseppe Gritti, Alessandro Rambaldi, Martino Introna, Paul W.H.I. Parren, Frank J. Beurskens, Josée Golay
Publikováno v:
Haematologica, Vol 100, Iss 1 (2015)
The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-δ inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combinati
Externí odkaz:
https://doaj.org/article/1c94da3a61174fd1bdb1a8cfcd711ad4
Autor:
Martino Introna, Paul W. H. I. Parren, Fabio Da Roit, Alessandro Rambaldi, Ronald P. Taylor, Giuseppe Gritti, Josée Golay, Frank J. Beurskens, Esther C.W. Breij, Patrick J. Engelberts
Publikováno v:
Da Roit, F, Engelberts, P J, Taylor, R P, Breij, E C, Gritti, G, Rambaldi, A, Introna, M, Parren, P W, Beurskens, F J & Golay, J 2015, ' Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy ', Haematologica, vol. 100, no. 1, pp. 77-86 . https://doi.org/10.3324/haematol.2014.107011
The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-δ inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb00af48e71c6ed89103d123792d3918
https://doi.org/10.3324/haematol.2014.107011
https://doi.org/10.3324/haematol.2014.107011
Autor:
Claudia Ferrara, Luca Bologna, Jeanette H. W. Leusen, Alessandro Rambaldi, Martino Introna, Christian Klein, Fabio Da Roit, Josée Golay
Publikováno v:
Blood. 122:3482-3491
Background Obinutuzumab (GA101) is a third generation, glycoengineered defucosylated anti-CD20 antibody which shows higher binding affinity for CD16A than fully glycosylated rituximab (RTX). This higher binding leads to stronger NK mediated antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54c784dd21a73e88335234fc64f70cbb
https://doi.org/10.1182/blood-2013-05-504043
https://doi.org/10.1182/blood-2013-05-504043